Is TCRX or IBIO more profitable?

iBio has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. iBio's return on equity of -40.66% beat TScan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TScan Therapeutics -1,655.35% -108.72% -54.47% iBio N/A -40.66% -35.78%

Do analysts recommend TCRX or APLM?

TScan Therapeutics presently has a consensus target price of $2.67, indicating a potential upside of 1,020.45%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe TScan Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, TCRX or APLM?

Apollomics has lower revenue, but higher earnings than TScan Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TScan Therapeutics $10.32M 1.56 -$129.77M -$0.91 N/A Apollomics $8.50M 7.64 -$10.94M N/A N/A

Do analysts recommend XBIT or TCRX?

TScan Therapeutics has a consensus target price of $2.67, suggesting a potential upside of 1,020.45%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TScan Therapeutics 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13

TScan Therapeutics (TCRX) Competitors

$0.24 +0.01 (+2.52%)

As of 02:04 PM Eastern

Compare

TCRX vs. GANX, RNTX, IBIO, APLM, and XBIT

Should you buy TScan Therapeutics stock or one of its competitors? TScan Therapeutics's main competitors and comparable companies include Gain Therapeutics (GANX), Rein Therapeutics (RNTX), iBio (IBIO), Apollomics (APLM), and XBiotech (XBIT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TScan Therapeutics compare to Gain Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Gain Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	1.56	-$129.77M	-$0.91	N/A
Gain Therapeutics	$50K	1,431.39	-$20.16M	-$0.50	N/A

Gain Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. TScan Therapeutics' return on equity of -108.72% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Gain Therapeutics	N/A	-161.59%	-118.36%

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

TScan Therapeutics currently has a consensus price target of $2.67, suggesting a potential upside of 1,020.45%. Gain Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 367.48%. Given TScan Therapeutics' higher probable upside, equities research analysts plainly believe TScan Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

TScan Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

In the previous week, Gain Therapeutics had 4 more articles in the media than TScan Therapeutics. MarketBeat recorded 5 mentions for Gain Therapeutics and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.82 beat Gain Therapeutics' score of 0.86 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Very Positive
Gain Therapeutics	Positive

Summary

TScan Therapeutics beats Gain Therapeutics on 9 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

In the previous week, Rein Therapeutics and Rein Therapeutics both had 1 articles in the media. Rein Therapeutics' average media sentiment score of 1.82 equaled TScan Therapeutics'average media sentiment score.

Company	Overall Sentiment
Rein Therapeutics	Very Positive
TScan Therapeutics	Very Positive

Rein Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 655.67%. TScan Therapeutics has a consensus target price of $2.67, indicating a potential upside of 1,020.45%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Rein Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13

Rein Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Rein Therapeutics' return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 1.5% of Rein Therapeutics shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rein Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Rein Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
TScan Therapeutics	$10.32M	1.56	-$129.77M	-$0.91	N/A

Summary

Rein Therapeutics and TScan Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does TScan Therapeutics compare to iBio?

TScan Therapeutics (NASDAQ:TCRX) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

TScan Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, iBio has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

In the previous week, TScan Therapeutics and TScan Therapeutics both had 1 articles in the media. TScan Therapeutics' average media sentiment score of 1.82 beat iBio's score of 0.59 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Very Positive
iBio	Positive

iBio has lower revenue, but higher earnings than TScan Therapeutics. iBio is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	1.56	-$129.77M	-$0.91	N/A
iBio	$100K	560.14	-$33.04M	-$0.34	N/A

iBio has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. iBio's return on equity of -40.66% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
iBio	N/A	-40.66%	-35.78%

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 1.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TScan Therapeutics presently has a consensus target price of $2.67, indicating a potential upside of 1,020.45%. iBio has a consensus target price of $5.29, indicating a potential upside of 506.86%. Given TScan Therapeutics' higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
iBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Summary

iBio beats TScan Therapeutics on 10 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Apollomics?

TScan Therapeutics (NASDAQ:TCRX) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Apollomics has lower revenue, but higher earnings than TScan Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	1.56	-$129.77M	-$0.91	N/A
Apollomics	$8.50M	7.64	-$10.94M	N/A	N/A

TScan Therapeutics presently has a consensus target price of $2.67, indicating a potential upside of 1,020.45%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe TScan Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TScan Therapeutics has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

Apollomics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Apollomics' return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Apollomics	N/A	N/A	N/A

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Apollomics had 2 more articles in the media than TScan Therapeutics. MarketBeat recorded 3 mentions for Apollomics and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.82 beat Apollomics' score of 1.07 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Very Positive
Apollomics	Positive

Summary

TScan Therapeutics and Apollomics tied by winning 7 of the 14 factors compared between the two stocks.

How does TScan Therapeutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

XBiotech has higher earnings, but lower revenue than TScan Therapeutics. XBiotech is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
TScan Therapeutics	$10.32M	1.56	-$129.77M	-$0.91	N/A

TScan Therapeutics has a consensus target price of $2.67, suggesting a potential upside of 1,020.45%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13

XBiotech has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

XBiotech has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. XBiotech's return on equity of -31.62% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 30.8% of XBiotech shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, XBiotech and XBiotech both had 1 articles in the media. TScan Therapeutics' average media sentiment score of 1.82 beat XBiotech's score of 1.79 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
XBiotech	Very Positive
TScan Therapeutics	Very Positive

Summary

TScan Therapeutics beats XBiotech on 9 of the 14 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRX vs. The Competition

Export

Metric	TScan Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.61M	$3.92B	$7.24B	$13.22B
Dividend Yield	N/A	3.65%	2.53%	22.58%
P/E Ratio	-0.27	13.53	275.62	25.87
Price / Sales	1.62	1,176.76	580.40	79.65
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	0.11	17.37	10.84	6.11
Net Income	-$129.77M	-$22.69M	$3.50B	$380.72M
7 Day Performance	-16.69%	-2.80%	-1.85%	-2.16%
1 Month Performance	-23.22%	-8.97%	-4.63%	-4.09%
1 Year Performance	-88.87%	13.21%	6.16%	0.67%

TScan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRX TScan Therapeutics	3.7624 of 5 stars	$0.24 +2.5%	$2.67 +992.9%	-89.2%	$16.54M	$10.32M	N/A	142	Positive News
GANX Gain Therapeutics	1.9332 of 5 stars	$1.70 +0.3%	$7.50 +342.5%	-16.8%	$73.98M	N/A	N/A	21
RNTX Rein Therapeutics	2.9624 of 5 stars	$0.82 -0.7%	$6.00 +632.6%	-38.9%	$70.66M	N/A	N/A	10	Positive News Gap Down
IBIO iBio	2.6192 of 5 stars	$1.05 -6.7%	$5.29 +405.8%	N/A	$67.85M	$100K	N/A	23	Gap Up
APLM Apollomics	1.8929 of 5 stars	$22.88 -1.7%	N/A	N/A	$66.58M	$8.50M	N/A	15	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRX) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TScan Therapeutics (TCRX) Competitors

TCRX vs. GANX, RNTX, IBIO, APLM, and XBIT

How does TScan Therapeutics compare to Gain Therapeutics?

Summary

How does TScan Therapeutics compare to Rein Therapeutics?

Summary

How does TScan Therapeutics compare to iBio?

Summary

How does TScan Therapeutics compare to Apollomics?

Summary

How does TScan Therapeutics compare to XBiotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TScan Therapeutics (TCRX) Competitors

TCRX vs. GANX, RNTX, IBIO, APLM, and XBIT

How does TScan Therapeutics compare to Gain Therapeutics?

Which has preferable valuation & earnings, TCRX or GANX?

Is TCRX or GANX more profitable?

Do institutionals & insiders hold more shares of TCRX or GANX?

Do analysts prefer TCRX or GANX?

Which has more risk & volatility, TCRX or GANX?

Does the media favor TCRX or GANX?

Summary

How does TScan Therapeutics compare to Rein Therapeutics?

Does the media prefer RNTX or TCRX?

Do analysts rate RNTX or TCRX?

Is RNTX or TCRX more profitable?

Do insiders & institutionals believe in RNTX or TCRX?

Which has more volatility and risk, RNTX or TCRX?

Which has preferable valuation & earnings, RNTX or TCRX?

Summary

How does TScan Therapeutics compare to iBio?

Which has more risk & volatility, TCRX or IBIO?

Does the media refer more to TCRX or IBIO?

Which has higher valuation and earnings, TCRX or IBIO?

Is TCRX or IBIO more profitable?

Do institutionals and insiders have more ownership in TCRX or IBIO?

Do analysts rate TCRX or IBIO?

Summary

How does TScan Therapeutics compare to Apollomics?

Which has better earnings & valuation, TCRX or APLM?

Do analysts recommend TCRX or APLM?

Which has more risk and volatility, TCRX or APLM?

Is TCRX or APLM more profitable?

Do institutionals & insiders believe in TCRX or APLM?

Does the media favor TCRX or APLM?

Summary

How does TScan Therapeutics compare to XBiotech?

Which has stronger valuation and earnings, XBIT or TCRX?

Do analysts recommend XBIT or TCRX?

Which has more risk and volatility, XBIT or TCRX?

Is XBIT or TCRX more profitable?

Do institutionals & insiders hold more shares of XBIT or TCRX?

Does the media refer more to XBIT or TCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools